Skip to content
MarketScale
‹ Back to Industries

Sciences

How Optical Sensors Will Change the World

Optical sensors are changing the way that we interact with the world. They are emerging to play a vital role in manufacturing automation, consumer electronics, energy production, and more. Industry professionals continue to push boundaries and find new ways to make optical sensors work better than ever. Soon, optical sensor manufacturers will use this technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
How Optical Sensors Will Change the World

Key takeaways

01

Optical sensors are changing the way that we interact with the world.

02

They are emerging to play a vital role in manufacturing automation, consumer electronics, energy production, and more.

03

Industry professionals continue to push boundaries and find new ways to make optical sensors work better than ever.

Optical sensors are changing the way that we interact with the world. They are emerging to play a vital role in manufacturing automation, consumer electronics, energy production, and more. Industry professionals continue to push boundaries and find new ways to make optical sensors work better than ever.

Soon, optical sensor manufacturers will use this technology to perform high-speed, continuous inspections on everything imaginable. Size, configuration, and material composition will be no obstacle. Just as optical fibers revolutionized the communications industry, hi-tech professionals can expect to see this technology impact sensors and high-powered lasers. This shift toward optical sensors won’t take long; experts expect the industry to see exceptional growth by 2025.

New Custom Sensors

They say that necessity drives innovation, and that has certainly been the case for optical sensors. As developers continue to demand fiber optics for more specific applications, manufacturers like Fiberguide are transforming to meet customer needs.

Customized specifically for the purpose in which they are commissioned, leaders in the industry are building fibers in many different shapes, materials, and sizes. Some offer higher speed, others are incredibly small, and others are being manufactured at significantly less cost than their predecessors. With each new application, the industry improves. As technology continues to boom in our society and demand grows, professionals can expect more innovation in fiber optic sensing.

Benefits of Fiber Sensors Over Competitors

Unlike other sensors, which only take measurements at certain points, most fiber sensors operate continuously, taking measurements uninterruptedly. This precision allows for incredible leaps in 3D printing and other technologies that require exactitude.

Some fiber sensors now use interferometric configurations, which allow incredible range, sensitivity and accuracy. These configurations work using interference between two separate beams. These beams can either propagate through two different paths in the same fiber or through two fibers. The result is a sensor that works well in sensitive industries, such as biometrics.

Denser Data

Thanks to customized sensors and new capabilities with lasers and white light, fiber optic technology will soon be able to send more data in a short time. This innovation is set to have a positive, lasting impact for the world of metrology. One study has already found real-world applications for this technology in the naval, aeronautical, and automotive industries.

Fiberguide’s Role

It’s clear that specialty fibers will bring incredible change across a variety of industries. Fiberguide Industries currently manufactures over 500 unique optical fiber parts, and continues to innovate to meet customer demands. We produce parts for a variety of technologies, including photonics, power delivery, and data communications. More recently, Fiberguide has begun building FBG-based fiber optic sensors, and is working to marry this technology to our expertise in high temperature fiber. This promises to yield FBG-based sensors with unmatched performance in high temperature environments. Learn more about Fiberguide and our optical fibers today.

Read more at fiberguide.com

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences